A detailed history of Royal Bank Of Canada transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 58 shares of ACRS stock, worth $220. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58
Previous 4,247 98.63%
Holding current value
$220
Previous $4,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.12 - $1.4 $4,691 - $5,864
-4,189 Reduced 98.63%
58 $0
Q2 2024

Aug 14, 2024

BUY
$1.01 - $1.36 $1,294 - $1,743
1,282 Added 43.24%
4,247 $4,000
Q1 2024

Nov 05, 2024

SELL
$0.92 - $1.44 $1,179 - $1,846
-1,282 Reduced 30.19%
2,965 $3,000
Q1 2024

May 15, 2024

SELL
$0.92 - $1.44 $18,789 - $29,409
-20,423 Reduced 87.32%
2,965 $3,000
Q4 2023

Feb 14, 2024

BUY
$0.64 - $6.49 $6,453 - $65,438
10,083 Added 75.78%
23,388 $24,000
Q3 2023

Nov 14, 2023

BUY
$6.56 - $10.95 $48,117 - $80,318
7,335 Added 122.86%
13,305 $91,000
Q2 2023

Aug 14, 2023

BUY
$7.89 - $10.64 $11,322 - $15,268
1,435 Added 31.64%
5,970 $61,000
Q1 2023

May 15, 2023

SELL
$7.07 - $17.95 $20,990 - $53,293
-2,969 Reduced 39.57%
4,535 $36,000
Q4 2022

Feb 14, 2023

BUY
$14.33 - $18.37 $95,624 - $122,583
6,673 Added 803.01%
7,504 $118,000
Q3 2022

Nov 14, 2022

BUY
$13.07 - $18.22 $6,325 - $8,818
484 Added 139.48%
831 $13,000
Q2 2022

Aug 15, 2022

SELL
$10.16 - $17.08 $28,346 - $47,653
-2,790 Reduced 88.94%
347 $5,000
Q1 2022

May 16, 2022

SELL
$9.74 - $17.92 $73,926 - $136,012
-7,590 Reduced 70.76%
3,137 $54,000
Q4 2021

Feb 14, 2022

BUY
$12.27 - $18.49 $68,478 - $103,192
5,581 Added 108.45%
10,727 $156,000
Q3 2021

Nov 15, 2021

BUY
$13.38 - $18.8 $29,061 - $40,833
2,172 Added 73.03%
5,146 $93,000
Q2 2021

Aug 16, 2021

BUY
$17.08 - $29.6 $50,795 - $88,030
2,974 New
2,974 $52,000

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $253M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.